NI202100009A - Métodos para reducir la necesidad de revascu - Google Patents

Métodos para reducir la necesidad de revascu

Info

Publication number
NI202100009A
NI202100009A NI202100009A NI202100009A NI202100009A NI 202100009 A NI202100009 A NI 202100009A NI 202100009 A NI202100009 A NI 202100009A NI 202100009 A NI202100009 A NI 202100009A NI 202100009 A NI202100009 A NI 202100009A
Authority
NI
Nicaragua
Prior art keywords
need
revascu
methods
reduce
subject
Prior art date
Application number
NI202100009A
Other languages
English (en)
Inventor
granowitz Craig
Philip Sephy
Original Assignee
Amarin Pharmaceuticals Ie Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarin Pharmaceuticals Ie Ltd filed Critical Amarin Pharmaceuticals Ie Ltd
Publication of NI202100009A publication Critical patent/NI202100009A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

En diversas realizaciones, la presente descripción proporciona métodos para diagnosticar la necesidad de revascularización arterial periférica y/o reducir la necesidad de revascularización arterial periférica en un sujeto mediante la administración al sujeto de una composición farmacéutica que comprende aproximadamente 1 g a aproximadamente 4 g de éster etílico del ácido eicosapentaenoico o un derivado del mismo.
NI202100009A 2018-08-17 2021-02-16 Métodos para reducir la necesidad de revascu NI202100009A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862719404P 2018-08-17 2018-08-17

Publications (1)

Publication Number Publication Date
NI202100009A true NI202100009A (es) 2021-06-22

Family

ID=69524891

Family Applications (1)

Application Number Title Priority Date Filing Date
NI202100009A NI202100009A (es) 2018-08-17 2021-02-16 Métodos para reducir la necesidad de revascu

Country Status (18)

Country Link
US (1) US20220362200A1 (es)
EP (1) EP3836914A4 (es)
JP (1) JP2021534185A (es)
KR (1) KR20210047312A (es)
CN (1) CN112912071A (es)
AU (1) AU2019321568A1 (es)
BR (1) BR112021002884A2 (es)
CA (1) CA3109774A1 (es)
CL (3) CL2021000400A1 (es)
EA (1) EA202190547A1 (es)
IL (1) IL280643A (es)
MA (1) MA52680A1 (es)
MX (1) MX2021001906A (es)
NI (1) NI202100009A (es)
PH (1) PH12021550328A1 (es)
SG (1) SG11202101562UA (es)
TN (1) TN2021000028A1 (es)
WO (1) WO2020037153A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
CN106822080A (zh) 2009-04-29 2017-06-13 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SG10201708950XA (en) 2009-06-15 2017-12-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (en) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
JP2015522029A (ja) 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN112218630A (zh) 2018-09-24 2021-01-12 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
US20210153817A1 (en) * 2019-11-21 2021-05-27 Avive Solutions, Inc. Device based responder network activation and virtual assistant integration
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
EP4329742A1 (en) * 2021-04-29 2024-03-06 Amarin Pharmaceuticals Ireland Limited Compositions comprising epa and methods of using the same for treating and/or preventing endothelial dysfunction in a subject

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090239927A1 (en) * 2004-12-06 2009-09-24 George Bobotas Statin and Omega-3 Fatty Acids For Lipid Therapy
EP2068861A4 (en) * 2006-07-21 2010-01-06 Reliant Pharmaceuticals Inc COMPOSITIONS COMPRISING OMEGA-3 FATTY ACIDS AND USE THEREOF IN THE TREATMENT OF PERIPHERAL ARTERIES DISEASE AND INTERMITTENT CLAUDICATION
JP2015522029A (ja) * 2012-06-29 2015-08-03 アマリン ファーマシューティカルス アイルランド リミテッド スタチン療法中の患者における心血管系イベントの危険性を減少させる方法
US20140322314A1 (en) * 2013-04-29 2014-10-30 Matinas Biopharma, Inc. Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment
US20150284473A1 (en) * 2014-03-17 2015-10-08 Laurence Bessac Methods for reducing cardiovascular risk
US10406130B2 (en) * 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
PL3275438T3 (pl) * 2016-07-29 2021-05-17 Kowa Company, Ltd. Sposoby zapobiegania zdarzeniom sercowo-naczyniowym w populacjach dyslipidemicznych z ryzykiem rezydualnym

Also Published As

Publication number Publication date
CN112912071A (zh) 2021-06-04
EA202190547A1 (ru) 2021-04-27
BR112021002884A2 (pt) 2021-05-11
IL280643A (en) 2021-03-25
SG11202101562UA (en) 2021-03-30
CL2021000400A1 (es) 2021-07-02
WO2020037153A1 (en) 2020-02-20
MX2021001906A (es) 2021-04-28
KR20210047312A (ko) 2021-04-29
AU2019321568A1 (en) 2021-03-11
MA52680A1 (fr) 2021-11-30
CA3109774A1 (en) 2020-02-20
EP3836914A1 (en) 2021-06-23
TN2021000028A1 (en) 2022-10-03
PH12021550328A1 (en) 2021-10-04
EP3836914A4 (en) 2022-05-18
CL2021003222A1 (es) 2022-07-22
CL2021003221A1 (es) 2022-07-22
JP2021534185A (ja) 2021-12-09
US20220362200A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
NI202100009A (es) Métodos para reducir la necesidad de revascu
CL2023000767A1 (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto.
NI201400155A (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto con terapia con estatina
MX2022005467A (es) Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto con fibrilación auricular y/o aleteo auricular.
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
UY37861A (es) Agentes antivirales contra la hepatitis b
AR105493A1 (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
ECSP099039A (es) Esteres de dha y su utilización en el tratamiento y la prevención de enfermedades cardiovasculares
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR114418A1 (es) Compuesto cíclico de metilactama y su utilización farmacéutica
BR112017015613A2 (pt) gel intestinal de levodopa e carbidopa e métodos de utilização
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
AR095538A1 (es) Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.
BR112021011368A2 (pt) Cocristal de cetoprofeno, composições compreendendo o mesmo, processo para a sua produção e usos dos mesmos
PH12021500016A1 (en) Methods of reducing the risk of cardiovascular events in a subject
ES2524645B1 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
CO2023000194A2 (es) Administración de sulcardina para el tratamiento de fibrilación auricular aguda
CL2023001739A1 (es) Ésteres de ácidos dicarboxílicos para el tratamiento de enfermedades y padecimientos asociados con la toxina
CL2023001737A1 (es) Ésteres de ácido dicarboxílico para inducir un efecto analgésico
CY1124107T1 (el) Συνδυασμος αδαπαλενης και υπεροξειδιου του βενζολιου για τη θεραπευτικη αντιμετωπιση της σοβαρης ακμης
EA202191612A1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
AR100621A1 (es) COMPUESTO INHIBIDOR DE FOSFOINOSÍTIDO-3-QUINASA d, COMPOSICIÓN FARMACÉUTICA, USO, MÉTODO
BR112015029693A2 (pt) formulações farmacêuticas de um inibidor de hif hidroxilase